Proxy Results (Form 8-K)

On June 10, 2026, Gyre Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on April 16, 2026, the record date for the Annual Meeting, there were 96,994,001 shares of common stock entitled to vote at the meeting.

At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved. The proposals are described in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 27, 2026. The final voting results are set forth below.

Proposal 1: Election of Directors

The following Class II director nominees were elected to serve until the 2029 Annual Meeting of Stockholders based upon the following votes:

Proposal 2: Non-Binding Advisory Vote on Executive Compensation

The compensation of the Company's named executive officers was approved, on a non-binding, advisory basis, as follows:

Proposal 3: Ratification of Independent Auditor

The appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified as follows:

Proposal 4: Approval of Conversion of Series B Preferred Stock

The issuance of shares of the Company's common stock, par value $0.001 per share, upon conversion of the Company's Series B Convertible Preferred Stock, par value $0.001 per share, was approved, in accordance with Nasdaq Listing Rule 5635(a), as follows:

2